Return to flip book view
AANP Regional Scientific Symposium 2024 PROGRAMME BOOKDownload e-bookOrganizer: Co-organizers: Society Sponsors:Supporting Organization:
CMYCMMYCYCMYKSpravato Ad(A4)_AW_240625_4iC_3026_OP.pdf 1 25/6/2024 3:41 PM
Table of ContentsWelcome Message from AANP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3Mission of AANP / Meeting Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5Meeting Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7Programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8–9Floor Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11CME/CNE Accreditation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13Presentation Abstracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15–30General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33Acknowledgement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 371
292.5% 10 LESS ONE-YEAR Relapse Free Rate3With NO NEW SAFETY Signals vs 3-monthly dosing regimen3*INJECTIONS Each Yearvs 1-monthly dosing regimenA NEW H PEfor your patients with the 6-monthly Injectable Therapy for Schizophrenia1,2 FIRST & ONLY *INVEGA HAFYERA® compared with INVEGA TRINZA®3References: 1. INVEGA HAFYERA® Hong Kong Prescribing Information P01. 2. Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia. 2021. Available at: https://www.jnj.com/media-center/press-releases/janssen-announces-u-s-fda-approval-of-invega-hafyera-6-month-paliperidone-palmitate-first-and-only-twice-yearly-treatment-for-adults-with-schizophrenia. 3. Najarian D et al. Int J Neuropsychopharmacol 2022:25; 238–251. 4. INVEGA SUSTENNA® Hong Kong Prescribing Information P11. For Healthcare Professionals Use Only | For INVEGA HAFYERA® abbreviated prescribing information, please scan the QR code.Johnson & Johnson (Hong Kong) Ltd13/F, Tower 1, Grand Century Place, 193 Prince Edward Road West, Mongkok, Hong KongTel: 2736 1711 Fax: 2736 1926© 2024 Johnson & JohnsonCP-457516 Jul 2024
3Welcome Message from AANP3Dear Colleagues,It is with great enthusiasm that I welcome you to the Asian Association of Neuropsychopharmacology’s (AANP) first Regional Scientific Symposium since the onset of the COVID-19 pandemic. Aer a lengthy hiatus since our last conference in 2018, we are excited to finally reconnect and engage with our esteemed colleagues in the industry.This year’s symposium, held at the Grand Ballroom, Level 2, The Langham Hong Kong, from October 25th to 27th, 2024, promises to be an enriching experience. With around 200 registrants, we have the unique opportunity to foster discussions and exchange insights on the latest advancements in our field.Our gathering will feature both international and local experts who will share their valuable experiences and knowledge on pressing clinical topics related to the diagnosis, treatment, and management of mood disorders and psychotic illnesses. The central theme, “Navigating Psychiatric Treatment in the New Era of Neuropsychopharmacology,” reflects our commitment to exploring innovative approaches in psychiatric care and enhancing our understanding of neuropsychopharmacology.As we embark on this journey of learning and collaboration, I encourage you to actively participate in the sessions, engage in discussions, and network with your peers. Together, we can make significant strides in advancing our field and improving patient care.Thank you for joining us, and I look forward to an inspiring and productive symposium!With best regards,Dr. Michael Wong Ming-CheukChairman, Asian Association of Neuropsychopharmacology (AANP)– Hong Kong Chapter
5Mission of AANPMeeting CommitteeThe Society aims to become the recognized forum to foster ongoing local and international collaboration on education with the intent to advance the treatment of all aspects of mood disorder and psychotic illnesses, particularly schizophrenia and to improve outcomes and quality of life for those suering from psychiatric illnesses and their carers or family members.Organizing Committee:Prof. Daniel Mak Ki-Yan, Dr. Billy Law Sai-On, Dr. Jackie Fu Chi-Kin, Dr. Wong Chi-KeungScientific Committee:Dr. Michael Wong Ming-Cheuk, Dr. Eric Cheung Yat-Wo, Dr. Ben Cheung Kin-LeungDr. Patrick Kwong Po-Keung, Dr. Lam Ho-Bun, Dr. Lee Yiu-Ki, Prof. M.S. Reddy (India)Financial Committee:Dr. Sham Shiu-Kow, Dr. Tse Sut-YeeSecretariat:Best Solution Co. Ltd.Regional AdvisorsProf. Ji Jianlin (China) , Prof. Xu Guiyun (China),Prof. M.S. Reddy (India), Prof. Nurmiati Amir (Indonesia), Prof. Margarita M. Maramis (Indonesia),Prof. Won-Myong Bahk (Korea), Prof. Duk-In Jon (Korea), Dr. João Piçarra (Macau)Dr. Hazli Zakaria (Malaysia), Prof. Thambu Maniam (Malaysia),Prof. Paul Lee (the Philippines), Dr. Orville Jess Pandes (the Philippines),Prof. Lee Cheng (Singapore), Prof. Lee Yu-Wei (Singapore),Prof. Chou Yuan-Hwa (Taiwan), Dr. Yip Chi-Pin (Taiwan), Prof. Pichet Udomratn (Thailand)
7Meeting InformationDate: 25 October, 2024 (Friday), 18:15 to 22:0026 October, 2024 (Saturday), 09:00 to 21:0027 October, 2024 (Sunday), 09:00 to 14:00Venue: The Grand Ballroom, Level 2, The Langham, Hong Kong(8 Peking Road, Tsimshatsui, Kowloon, Hong Kong)Organizer: Asian Association of Neuropsychopharmacology (AANP)Co-organizers: Society for Advancement of Bipolar Aective Disorder (SABAD)The Hong Kong College of Mental Health Nursing (HKCMHN)Society Sponsors:The Hong Kong Association of Psychosocial Rehabilitation (HKAPR)Hong Kong Society of Biological Psychiatry (HKSBP)Supporting Organization:The Hong Kong Society of Psychiatrists (HKSP)
8ProgrammeProf. Siu-Wa TANG(Emeritus Professor of Psychiatry, University of California,Irvine, CA, USA)Mr. HangCHEN and Ms. Shuneng GU (Representatives, BOKE) THEME: DEPRESSION12:00 –13:00 New Treatment of Schizophrenia and MDD – Using SDAM (Serotonin Dopamine Activity Modulators) to Bring Remission THEME: ADHD13:00–14:00 Lunch Symposium – Advancing ADHD Diagnostics through Gamification: Introduction and Clinical Practice of BOKE CPT+26OCTOBER(Saturday)SPEAKERSTIME TOPICSProf. Daniel Ki-Yan MAK(AANP, Secretariat (Officer-in-charge), Hong Kong)18:15 Start Reception / Welcome Cocktail THEME: ANTIPSYCHOTIC (PART 1) 19:00–19:15 Welcome RemarksDr. Michael Ming-Cheuk WONG(Specialist in Psychiatry, HK)Prof. Ofer AGID(Associate Professor, Neurosciences and Clinical Translation, University of Toronto, Canada)19:15 –20:15 Dinner Symposium – Real-World Effectiveness of Long-Acting Injectable (LAI) Antipsychotics and Implementing Shared Decision-Making (SDM) in Clinical Practice17:00–18:30 AANP Annual General Meeting (Part 1)2520:15–20:45 LAI SDM Case Sharing20:30–22:00 Welcome Dinner 09:30–10:00 Opening Ceremony 9:00 Start ReceptionProf. Kangguang LIN(Chief Physician/Professor, Department of Affective Disorder, The Affiliated Brain Hospital of GuangzhouMedical University Professor, The University of Health and Rehabilitation Sciences, China)Dr. Michael Ming-Cheuk WONG(Chairman, AANP-HK Chapter)10:00 –10:30 THEME SPEECH: The Future of Psychiatric Drug: More Specific or More BoardSpectrum?10:30–11:30 Illness, At-risk, and Resilience Biomarkers of Early-Stage Bipolar I Disorder in Children and AdolescentsProf. Cheng LEE JP(Adjunct Associate Professor,Senior Consultant, PsychiatristClinical Director, Office of Population HealthInstitute of Mental Health, Singapore)Dr. Chi-Keung WONG(Specialist in Psychiatry, HK)14:00–14:30 Clinical Experience Sharing on the Use of Continuous Performance Test in ADHD Diagnosis and Management THEME: ANTIPSYCHOTIC (PART 2)14:30–15:00 The Use of Antipsychotics in Bipolar Disorders15:00–15:30 Rational Use of Antipsychotics for Depressive Disorder 11:30–12:00 Tea BreakDr. Yiu-Ki LEE(Specialist in Psychiatry, HK)
9ProgrammeDr. Pongsatorn PAHOLPAK(Psychiatrist, Attending physician, Department of Psychiatry, Faculty of Medicine, Khon Kaen University, Thailand)Prof. M.S. REDDY(Consultant Psychiatrist, Asha Hospital, India) THEME: BIPOLAR PRESCRIPTION MATTERS (Supported by SABAD)9:00 Start Reception THEME: ANTIDEPRESSANT (Supported by SABAD) PRESS CONFERENCE11:00–11:30 Paradigm Shift in the Management of Bipolar Disorders – Are We Ready? 10:00–11:00 Understanding Mixed States in Bipolar DisorderProf. Daniel Ki-Yan MAK(AANP Representative, Asia)Dr. Tak-Lam LO(Specialist in Psychiatry, HK)Prof. M.S. REDDY(Consultant Psychiatrist, Asha Hospital, India)12:00–13:00 Achieving Full Functional Recovery and Additional Treatment Goals for Patients with Major DepressiveDisorder(MDD)13:45 Start Reception for Press Conference11:30–12:00 Tea Break09:00–10:00 AANP Annual General Meeting (Part 2)26OCTOBER(Saturday)27OCTOBER(Sunday)13:00–13:15 AANP Regional Scientific Symposium 2024 Declaration: Committing to a World Without War – Signatures for Peace StatementsDr. Eric Yat-Wo CHEUNG(Chairman, SABAD)Dr. Eric Yat-Wo CHEUNG, Dr. Chi-Kin FUProf. Cheng LEE(Specialists in Psychiatry, Representatives of AANP-Asia)13:45 - 14:00 Closing Remarks14:15–15:15 憂鬱病有得醫 (Including Q&A)13:15–13:45 Lunch Symposium – Transcranial Magnetic Stimulation (TMS) in the Treatment of MDD & OCDProf. Wing-Chung CHANG(Clinical Associate Professor, Department of Psychiatry, School of Clinical Medicine, The University of Hong Kong)17:00–18:00 Relapse Prevention in Psychotic Disorders and Differential Mortality Risk Associated with Antipsychotic TreatmentDr. Matthew Shun-Ming WONG(Specialist in Psychiatry, Honorary Clinical Assistant Professor, LKS Faculty of Medicine, The University of Hong Kong)Dr. Isaac Pui-Lam YIP(Specialist in Psychiatry, HK) THEME: SLEEP, SOMATIC & ANXIETY THEME: ANTIPSYCHOTIC (PART 3)15:30–15:50 Clinical Recommendations in the Use of Lemborexant16:30–17:00 Tea Break (Poster Presentation)15:50–16:30 When New Meets Old: Treatment for InsomniaDr. Alex WODAK(Emeritus Consultant, Alcohol and Drug Service, St Vincent's Hospital, Sydney, AustraliaDirector, Australian Tobacco Harm Reduction Association Ambassador, Harm Reduction Australia)19:30–21:00 Dinner Keynote Symposium – Drug Harm Reduction: What is it? Does it Work?IsitSafe? THEME: HARM REDUCTION18:00–19:30 Evening Session: Start Reception / CocktailSPEAKERSTIME TOPICSCommitting to a World Without War – Signatures forPeace Statements (Signature Ceremony)
CMYCMMYCYCMYKVyvanse Print Ads 2024 210x297_v2_OP130.pdf 1 30/1/2024 上午11:30
11Floor planBooth 1 – Pfizer Corporation Hong Kong Ltd.Booth 2 – DKSH Hong Kong Ltd. Booth 3 – Takeda Pharmaceuticals (Hong Kong) Ltd.Booth 4 – Lundbeck Hong Kong Ltd.Booth 5 – Lee’s Pharmaceutical (HK) Ltd. Booth 6 – Eisai Hong Kong Co., Ltd. Booth 7 – Servier Hong Kong Ltd. Booth 8 – Otsuka Pharmaceutical (H.K.) Ltd.Booth 9 – Johnson & Johnson (Hong Kong) Ltd.
AD-20240227-03For healthcare professional reference onlyPlease refer to the LATUDA full prescribing information by scanning the QR code.Indications1BIPOLAR I DEPRESSION• Adults 20-120 mg/day• Adolescents (13-17 years) 20-80 mg/daySCHIZOPHRENIA• Adults 40-160 mg/day• Adolescents (15-17 years) 40-80 mg/dayAbbreviations: BMI= Body Mass Index, DM= Diabetes Mellitus, ECG= Electrocardiography, HAM-A= Hamilton Anxiety Rating Scale, MADRS= Montagometry-Asberg Depression Rating Scale, QoL= Quality of Life, SDS= Sheehan Disability Scale, TEAE= Treatment-Emergent Adverse EventsReferences: 1. LATUDA® Hong Kong Prescribing Information. July 2021. 2. Loebel A, et al. Am J Psychiatry. 2014; 171(2):160-168.3. Loebel A, et al. Am J Psychiatry. 2014; 171(2): 169-177 4. Tocco M et al. CNS Spectr.2023;28(6):680-687. No initial dose titration is required1Distributed by DKSH Hong Kong23rd Floor, Tower A, Southmark, 11 Yip Hing Street,Wong Chuk Hang, Hong KongPhone: +852 2895 0888 Fax: +852 2577 1057For healthcare professional reference onlyWell-established Safety Profile1-4Well-established Safety Profile1-4Low Occurrence of Serious AEs2,3No or Minimal Noticeable Eect on Weight and Meta-bolic Parameters1,2,4For the treatment of schizophrenia and bipolar I depressionA ONCE-DAILY oral atypical antipsychotic1Proven Ecacy in Bipolar I Depression2,3Proven Ecacy in Bipolar I Depression2,3*compared to placebo at week 6 ^with lithium/valproateReduction in Depressive Symptoms2-3Alleviation of Anxiety Symptoms2-3greater reduction in MADRS score in monotherapy*greater reduction in MADRS score in adjunctive therapy*^in HAM-A in monotherapy with 20 - 60 mg/day*44%44%in SDS in monotherapy*Improvement in Functional Impairment2-350%50% in SDS in adjunctive therapy*^35%35%QoL enjoyment and satisfaction in monotherapy*Better Quality of Life (QoL)2-350%50%QoL enjoyment and satisfaction in adjunctive therapy*^39%39%48%48%in HAM-A in adjunctive therapy*^33%33%27%27%Restoring BalanceTransforming Lives
13CME/CNE AccreditationCollege/ProgrammeMax. for whole function25 Oct19:0020:45CME / CNE pts.26 Oct 9:30–21:00CME / CNE pts.27 Oct10:00–14:00CME / CNE pts.CategoryThe Hong Kong College of AnaesthesiologistsUnder ApprovalHong Kong College of Community Medicine10 1.5 6 3 PP-PPHong Kong College of Emergency MedicineUnder ApprovalThe Hong Kong College of Family PhysiciansUnder ApprovalThe Hong Kong College of Obstetricians and Gynaecologists5 1.5 5 3 PP-PNThe College of Ophthalmologists of Hong KongUnder ApprovalThe Hong Kong College of Otorhinolaryngologists7 1 4.5 1.5 PP-2.2The Hong Kong College of Pathologists13 1.5 8.5 3 CME-PPHong Kong College of PhysiciansUnder ApprovalThe Hong Kong College of Psychiatrists10.5 1.5 6 3 PP-CPHong Kong College of Radiologists13 1.5 8.5 3 B-PPThe College of Surgeons of Hong Kong11 1.5 6 3.5 CME-PPMCHK (Hong Kong Academy of Medicine)10 2 5 3 PASSIVE CMECollege/ProgrammeMax. for whole function25 Oct19:0020:45CME / CNE pts.26 Oct AM9:30-14:30CME / CNE pts26 Oct PM14:30-21:00CME / CNE pts.27 Oct10:00–14:00CME / CNE pts.CategoryHong Kong College of Paediatricians10 1 3 3 3 A-PPCNE (provided by The HongKong College of Mental Health Nursing (HKCMHN))13 1.5 4 4.5 3 N/A
Say Goodnight to Insomnia with DAYVIGOHelp patients fall asleep fast and stay asleep longer with minimal residual morning eects2,3DAYVIGO is a DORA indicated for both sleep onset and maintenance by regulating the sleep-wake cycle.4Eisai (Hong Kong) Company LimitedUnit D, 18/F, Lee & Man Commercial Centre,169 Electric Road, North Point, Hong KongTel: (852) 2516 6128 | Fax: (852) 2561 5042References: 1. Takaesu Y, et al. Front Psychiatry 2023;14:1168100. 2. Yardley J, et al. Sleep Med 2021;80:333-342. 3. Moline M, et al. Postgrad Med 2021;133:71-81. 4. DAYVIGO® (lemborexant) [Prescribing Information]. Hong Kong: Eisai Hong Kong Co., Ltd; 2021. 5. Rosenberg R, et al. Am J Geriatr Psychiatry 2021;29:4S.DORA, dual orexin receptor antagonist; GABA, gamma aminobutyric acid.ABBREVIATED PRESCRIBED INFORMATION INDICATION. • DAYVIGO (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by diculties with sleep onset and/or sleep maintenance. CONTRAINDICATIONS • DAYVIGO is contraindicated in patients with narcolepsy. WARNINGS AND PRECAUTIONS • Central Nervous System (CNS) Depressant Eects and Daytime Impairment: • DAYVIGO can impair daytime wakefulness. CNS depressant eects may persist in some patients up to several days after discontinuing DAYVIGO. Prescribers should advise patients about the potential for next-day somnolence. • Driving ability was impaired in some subjects taking DAYVIGO 10 mg. Risk of daytime impairment is increased if DAYVIGO is taken with less than a full night of sleep remaining or if a higher than recommended dose. If taken in these circumstances, patients should be cautioned against driving and other activities requiring complete mental alertness. • Co-administration with other classes of CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression, which can cause daytime impairment. Dosage adjustments of DAYVIGO and concomitant CNS depressants may be necessary when administered together. Use of DAYVIGO with other drugs to treat insomnia is not recommended. Patients should be advised not to consume alcohol in combination with DAYVIGO. • Because DAYVIGO can cause drowsiness, patients, particularly the elderly, are at a higher risk of falls. Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, and Cataplexy-Like Symptoms: • Sleep paralysis, an inability to move or speak for up toseveral minutes during sleep-wake transitions, hypnagogic/hypnopompic hallucinations, including vivid and disturbing perceptions can occur with DAYVIGO. Prescribers should explain the nature of these events to patients when prescribing DAYVIGO.• Symptoms similar to mild cataplexy can occur with DAYVIGO and can include periods of leg weakness lasting from seconds to a few minutes, can occur either at night or during the day, and may not be associated with an identified triggering event (e.g., laughter or surprise). Complex Sleep Behaviours: • Complex sleep behaviours, including sleep-walking, sleep driving, and engaging in other activities while not fully awake (e.g., preparing and eating food, making phone calls, having sex), havebeen reported to occur with the use of hypnotics such as DAYVIGO. Events can occur in hypnotic-naïve and hypnotic-experienced persons. Patients usually do not remember these events. Complex sleep behaviours may occur following the rest or anysubsequent use of DAYVIGO, with or without the concomitant use of alcohol and other CNS depressants. Discontinue DAYVIGO immediately if a patient experiences a complex sleep behaviour. Patients with Compromised Respiratory Function: • Theeect of DAYVIGO on respiratory function should be considered for patients with compromised respiratory function. DAYVIGO has not been studied in patients with moderate to severe obstructive sleep apnoea (OSA) or chronic obstructive pulmonarydisease (COPD). Worsening of Depression/Suicidal Ideation: • Incidence of suicidal ideation or suicidal behaviour, as assessed by questionnaire, was higher in patients receiving DAYVIGO than placebo (0.3% for DAYVIGO 10 mg, 0.4% for DAYVIGO 5mg, and 0.2% for placebo). In primarily depressed patients treated with hypnotics, worsening of depression and suicidal thoughts and actions (including completed suicides) have been reported. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdose is more common in this group of patients; therefore, the lowest number of tablets that is feasible should be prescribed at any one time. The emergence of any new behavioural sign or symptom of concern requires careful and immediate evaluation. Need to Evaluate for Co-morbid Diagnoses: • Treatment of insomnia should be initiated only after careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia or the emergence of new cognitive or behavioural abnormalities may be the result of an unrecognized underlying psychiatric or medical disorder and can emerge during the course of treatment with sleep-promoting drugs such as DAYVIGO. ADVERSE REACTIONS • The most common adverse reaction (reported in 5% of patients treated with DAYVIGO and at least twice the rate of placebo) in one study and (10% for DAYVIGO 10 mg, 7% for DAYVIGO 5 mg, 1% for placebo) in another study was somnolence. DRUG INTERACTIONS • Drugs Having Clinically Important Interactions with DAYVIGO: • The maximum recommended dose of DAYVIGO is 5 mg no more than once per night when co-administered with weak CYP3A inhibitors. Avoid concomitant use of DAYVIGO with moderate or strong CYP3A inducers USE IN SPECIFIC POPULATIONS • Pregnancy: • There are no available data on DAYVIGO use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or foetal outcomes. Lactation: • There are no data on the presence of DAYVIGO in human milk, the eects on the breastfed infant, or the eects on milk production. Infants exposed to DAYVIGO through breastmilk should be monitored for excess sedation. Geriatric Use: • Exercise caution when using doses higher than 5 mg in patients - 65 years old. Renal Impairment: • Patients with severe renal impairment may experience an increased risk of somnolence. Hepatic Impairment: • The maximum recommended dose of DAYVIGO is 5 mg no more than once per night in patients with moderate hepatic impairment. DAYVIGO is not recommended in patients with severe hepatic impairment. Patients with mild hepatic impairment may experience an increased risk of somnolence. DRUG ABUSE AND DEPENDENCE • Abuse: • Individuals with a history of abuse or addiction to alcohol or other drugs may be at increased risk for abuse and addiction to DAYVIGO, follow such patients carefully. Dependence: • Chronic administration of DAYVIGO did not produce withdrawal signs or symptoms upon drug discontinuation. This suggests that DAYVIGO does not produce physical dependence. Please see the full Prescribing Information.5mg tablets5mg tabletsHK-DG-MM-23G-01Japanese expert consensus:1st line recommendation for both sleep initiation and maintenance insomnia1Improved sleep eciency, onset and maintenance2*Long-term benefits continued over 12 months2Successful next-dose transition from a GABA agonist† to DAYVIGO5Well tolerated in switch patients5Minimal residual eects on:3Driving capabilitiesMemoryPostural stabilityChronic treatment was not associated with physical dependence or withdrawal eects2,4Safety ProfileClinical Ecacy*Within the first week of treatment. †Immediate- and extended-release.
15Presentation AbstractsReal-World Eectiveness of Long-Acting Injectable (LAI) Antipsychotics and Implementing Shared Decision-Making (SDM) in Clinical PracticeProf. Ofer AGIDAssociate Professor, Neurosciences and Clinical Translation, University of Toronto, CanadaAbstract:The objectives of this presentation include exploring schizophrenia as a neurodevelopmental versus a neuroprogressive disorder and examining the role of Long-Acting Injectables (LAIs) in its treatment, with a focus on adherence versus non-adherence and the impact on relapse, as well as comparing LAIs with oral treatments. It also addresses the global utilization and underutilization of LAIs, and strategies for eectively “marketing” treatment ideas, drawing insights from the ‘Prelapse’ study and shared decision-making approaches.25 October 2024 (Friday)
16Presentation AbstractsTHEME SPEECH - The Future of Psychiatric Drug: More Specic or More Board Spectrum?Dr. Michael Ming-Cheuk WONGChairman, AANP-HK ChapterAbstract:In this theme speech, Dr. Michael Wong explores the evolving landscape of psychiatric medications, addressing the pivotal question: should future psychiatric drugs be more specific or encompass a broader spectrum of treatment? Dr. Wong will use the development of antipsychotic medications, in particular, as illustration. Drawing on recent advancements in the knowledge of the neurobiology and brain neurocircuits, and the development in therapeutic modalities, Dr. Wong will discuss the implications of developing targeted therapies that cater to specific psychiatric disorders versus the potential benefits of broad-spectrum medications that address multiple symptoms across various conditions. Dr. Wong’s presentation aims to stimulate discussion on how future drug development can best meet the diverse needs of patients while ensuring eicacy, safety, and accessibility. It is the aim of this discussion for the attendees to gain insights into the direction of psychiatric pharmacotherapy and its potential impact on mental health care in the coming years.26 October 2024 (Saturday)
17Presentation Abstracts26 October 2024 (Saturday)Abstract:In this presentation, Prof. Kangguang Lin delves into the critical identification of biomarkers linked to early-stage Bipolar I Disorder in children and adolescents. Focusing on three key categories—illness biomarkers, at-risk indicators, and resilience factors—this research aims to deepen our understanding of this complex mental health condition. Prof. Lin will present findings from a comprehensive study that integrates neurobiological, genetic, and psychosocial data, shedding light on how these elements interplay in the development of bipolar disorder. The significance of early diagnosis and intervention will be emphasized, particularly in recognizing at-risk youth who may benefit from targeted support. By fostering resilience, we can potentially mitigate the adverse eects of bipolar disorder on young individuals and their families. This presentation advocates for a multidimensional approach to enhance outcomes and promote mental well-being in this vulnerable population, highlighting the urgent need for further research in this area.Prof. Kangguang LINChief Physician/Professor, Department of Aective Disorder, The Ailiated Brain Hospital of Guangzhou Medical UniversityProfessor, the University of Health and Rehabilitation Sciences, ChinaIllness, At-risk, and Resilience Biomarkers of Early-Stage Bipolar I Disorder in Children and Adolescents
18Presentation Abstracts26 October 2024 (Saturday)Abstract:The commonest psychotropic drugs for mood disorders and schizophrenia exhibit potent action on serotonin (5HT) and dopamine (DA) targets. Given the complex and heterogeneous biological background of patients, it is not surprising that patients oen demonstrate dierent responses to the same drug, necessitating a switch. Oering clinicians a good choice of drugs with dierent pharmacological properties therefore becomes important. Although interactions of these drugs with the various 5HT and DA targets are complex, switching a patient not responding well or intolerant to drugs of similar pharmacology to other drugs with dierent pharmacological profiles is usually the best strategy. Many years ago, the atypical member of the atypical antipsychotics, aripiprazole, with its unique partial agonist receptor profile, oered an important solution when the traditional psychotropics with similar pharmacology failed. Modification of the aripiprazole molecule resulted in another new drug brexpiprazole with dierent 5HT and DA receptor profiles. Clinicians now have another important choice in treating patients suering from the two major psychiatric disorders. This talk will discuss choosing brexpiprazole over or in combination with other psychotropics in the treatment of mood disorders and schizophrenia based on its interesting pharmacology.Prof. Siu-Wa TANGEmeritus Professor of Psychiatry, University of California, Irvine, CA, USA.New Treatment of Schizophrenia and MDD - Using SDAM (Serotonin Dopamine Activity Modulators) to Bring Remission
19Presentation Abstracts26 October 2024 (Saturday)Abstract:Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder that poses significant challenges in diagnosis and management. Traditional diagnostic methods oen rely on subjective assessments and standardized questionnaires, which can overlook individual nuances. This lecture introduces how a computerized continuous performance test (CPT) that leverages gamification can enhance the ADHD diagnostic process.During this session, we will explore the underlying principles of gamification in clinical practice, discuss the methodology and validation of computerized CPT, and share case studies demonstrating its eectiveness in various clinical settings. Attendees will gain insights into how computerized CPT can be integrated into routine ADHD assessments, improving diagnostic accuracy and patient outcomes.Mr. Hang CHENRepresentative, BOKEMs. Shuneng GURepresentative, BOKEAdvancing ADHD Diagnostics through Gamication: Introduction and Clinical Practice of BOKE CPT+
20Presentation Abstracts26 October 2024 (Saturday)Abstract:In this engaging presentation, Dr. Lee Yiu Ki shares valuable clinical experiences regarding the implementation of Continuous Performance Tests (CPT) in the diagnosis and management of Attention Deficit Hyperactivity Disorder (ADHD). Through understanding the characteristics of CPT, both in terms of the strengths and limitation, Dr. Lee will provide insights on eective practical applications of it as a tool assisting clinical assessment of attentional control and impulsivity, so as to enhance a comprehensive diagnostic as well as individualized treatment process. By sharing best practices and lessons learned from real-world applications, this presentation aims to equip clinicians with the knowledge to eectively integrate CPT into their diagnostic and management framework.Dr. Yiu-Ki LEESpecialist in Psychiatry, HKClinical Experience Sharing on the Use of Continuous Performance Test in ADHD Diagnosis and Management
21Presentation Abstracts26 October 2024 (Saturday)Abstract:Bipolar Disorders are commonly underrecognized and underdiagnosed. Patients with Bipolar Disorders are symptomatic for almost half of their lives and they also have at least one other psychiatric disorder. Metabolic and cardiovascular comorbidities are common and they are at risk of premature deaths due to medical disorders and unnatural causes such as suicide, homicide, and accidents.Patients with Bipolar Disorders are typically prescribed a mood stabilizer, antipsychotic, or antidepressant — either as monotherapy or in combination. The first approved medication for the treatment of Bipolar Disorder was a mood stabilizer. The first approved antipsychotic for Bipolar Disorder was a typical antipsychotic. Today, nearly all antipsychotic prescriptions written for Bipolar Disorder are for atypical antipsychotics. Combination therapy is oen prescribed due to the complex and episodic nature of the disease, especially in patients with substantial depressive episodes.The EMBLEM (European Mania in Bipolar Longitudinal Evaluation of Medication) highlighted the high rate of treatment switch in Bipolar I Disorder. Common reasons for the switch included reasons such as ineectiveness and intolerability of the treatment as well as upon the request of the patient.As Bipolar Disorders are complex mood states characterised by a range of symptoms, clinicians need to understand the activity at neurotransmitter receptor sites which are postulated to help balance neurotransmitter levels throughout the brain. For example, partial agonists can act as either a functional agonist or antagonist at the receptor sites depending on the concentration of dopamine and serotonin. The proposed net eect of blocking of the dierent dopamine (D1, D2 and D3) would account for the eect in improvement in the positive, negative and mood symptoms.It is useful in distinguishing poor treatment adherence compared with poor response. There are deleterious eects of treatment non-adherence in Bipolar Disorders; the risk of relapse leading to hospitalization increases with the number of relapse episodes. A long acting injectable (LAI) would help to accurately monitor treatment adherence and leads to accurate dosing and maintenance of stable plasma levels of drug.In this presentation, an oral antipsychotic medication with stronger D3 ainity (Cariprazine) as well as a LAI (Aripiprazole once-monthly 400 mg) are used to illustrate the current trend in the use of antipsychotic medications in Bipolar Disorders.Prof. Cheng LEE JP Adjunct Associate ProfessorSenior Consultant, PsychiatristClinical Director, Oice of Population HealthInstitute of Mental Health SingaporeThe Use of Antipsychotics in Bipolar Disorders
22Presentation Abstracts26 October 2024 (Saturday)Abstract:Dr. Wong Chi Keung will present on the rational use of antipsychotics in the treatment of depressive disorders, guided by consensus statements from the Asian Association of Neuropsychopharmacology (AANP). This session will explore the strategic application of antipsychotics, focusing on their role in enhancing treatment outcomes for patients with depressive disorders, particularly those with treatment-resistant depression. Dr. Wong will discuss the criteria for selecting appropriate antipsychotics, balancing eicacy and safety, and managing potential side eects. He will also address the importance of personalized treatment plans and the integration of antipsychotics with other therapeutic modalities. Through examining current evidence and expert consensus, Dr. Wong aims to provide clinicians with practical insights into optimizing the use of antipsychotics, ensuring improved patient outcomes and quality of life. This presentation is essential for healthcare professionals seeking to refine their approach to managing complex depressive disorders with antipsychotic medications.Dr. Chi-Keung WONGSpecialist in Psychiatry, HKRational Use of Antipsychotics for Depressive Disorder
23Presentation Abstracts26 October 2024 (Saturday)Abstract:In this presentation, Dr. Isaac Yip will discuss the Asian Association of Neuropsychopharmacology (AANP)’s clinical recommendations on the rational use of lemborexant, a novel dual orexin receptor antagonist eective in treating insomnia. Lemborexant promotes sleep onset and maintenance, demonstrating improvements in sleep eiciency and latency to persistent sleep, as evidenced by polysomnography. Dr. Yip will address important considerations regarding drug-drug interactions due to its metabolism via the CYP3A system and will emphasize caution in patients with liver impairment or those breastfeeding. The safety profile of lemborexant in populations with renal impairment, obstructive sleep apnea, and among the elderly will also be highlighted. While mild side eects may occur, lemborexant does not significantly impair cognitive function and has no residual morning eects. This session aims to provide clinicians with essential insights for the eective and rational use of lemborexant in managing insomnia.Dr. Isaac Pui-Lam YIPSpecialist in Psychiatry, HKClinical Recommendations in the Use of Lemborexant
24Presentation Abstracts26 October 2024 (Saturday)Abstract:Insomnia disorder is characterized by diiculties in initiating and/or maintaining sleep, causing daytime impairment, and aecting social, occupational and other functioning. Insomnia is highly prevalent (39.4%) among Hong Kong Chinese adults, and is associated with frequent use of alcohol, poor mental health and quality of life. Insomnia can present independently or with other medical conditions such as psychiatric disorders, metabolic or cardiovascular diseases.International guidelines recommend cognitive behavioural therapy intervention (CBT-I) as the first-line treatment for insomnia. However, CBT-I may be ineective or unavailable (due to limited trained professionals), and thus pharmacological treatment may be warranted; pharmacotherapy and CBT-I can be used as complementary treatments for insomnia.Many current insomnia treatments such as benzodiazepines and benzodiazepine receptor agonists (Z-drugs) are associated with adverse consequences such as next-day impairment, confusion, and falls, especially in older people.Insomnia is associated with an abnormal state of hyperarousal (increased somatic, cognitive, and cortical activation) and orexin has been identified as a key promotor of arousal and vigilance. Orexin receptor antagonists (ORAs) have revolutionised the pharmacological treatment of insomnia because they not only improve sleep but appear to have no dependence or tolerance-inducing eects, which makes them suitable for long-term treatment. The safety and tolerability profile of ORAs clearly dier from those of more traditional sleep-promoting drugs.The pivotal clinical trials of lemborexant, a dual orexin receptor antagonist (DORA), have shown significant benefits on sleep onset and sleep maintenance, that were sustained over twelve months. Most treatment emergent adverse events were mild/moderate and there was no evidence of rebound insomnia or withdrawal, following treatment discontinuation. Also, a summary of findings across 9 clinical trials concluded that lemborexant did not substantially impair next-day functioning among healthy subjects and subjects with insomnia. Furthermore, lemborexant has demonstrated respiratory safety and was well tolerated in participants with moderate to severe obstructive sleep apnoea (OSA) and comorbid insomnia.Various comparative eectiveness studies, systematic reviews and/or network meta-analyses have identified that ORAs, such as lemborexant, have superior eicacy and safety, especially when used long-term and/or in elderly patients. Dr. Matthew Shun-Ming WONGSpecialist in PsychiatryHonorary Clinical Assistant Professor, LKS Faculty of Medicine, The University of Hong KongWhen New Meets Old: Treatment for Insomnia
25Presentation Abstracts26 October 2024 (Saturday)Abstract:Schizophrenia and other psychotic disorders are a group of severe mental disorders aecting approximately 2-3% of the population and are associated with pronounced functional disability, constituting one of the leading causes of disability worldwide. The disorders are potentially chronic in nature and are associated with high risk of relapse, resulting in functional deterioration, rehospitalizations or even increased likelihood of treatment refractoriness. Antipsychotic medications are the mainstay treatment for acute psychosis and relapse prevention. In this presentation, a review of an array of medication-related factors, including maintenance versus discontinuation of treatment, dose continuation versus dose reduction approach, role of long-acting injectable antipsychotic and other relevant factors in relation to relapse prevention will be discussed. In addition, substantial evidence has indicated that people suering from schizophrenia have markedly elevated risk of premature mortality, physical comorbidity and substantially shortened life expectancy relative to the general population. To shed light on the potential relationship between antipsychotics and excess mortality risk, research findings regarding the dierential mortality rate associated with various antipsychotic medications in a large cohort of people with schizophrenia in Hong Kong will be presented.Prof. Wing-Chung CHANGClinical Associate Professor, Department of Psychiatry,School of Clinical Medicine,The University of Hong KongRelapse Prevention in Psychotic Disorders and Dierential Mortality Risk Associated with Antipsychotic Treatment
26Presentation Abstracts26 October 2024 (Saturday)Abstract:In most countries, legal and illegal psychoactive drugs account for substantial health, social and economic costs. Health costs of tobacco far exceed those of alcohol and illegal drugs. Communities respond by measures to reduce supply, demand and harm. Supply reduction attracts the majority of government expenditure in response to illicit drugs even though eectiveness is weak and counterproductive eects pronounced. Harm reduction, i.e. directly reducing adverse consequences without necessarily changing consumption or behaviour, is oen dramatically eective for alcohol, tobacco and illicit drugs but is oen fiercely resisted. Tobacco harm reduction now promises to accelerate the global end of smoking. Dr. Alex WODAKEmeritus Consultant, Alcohol and Drug Service, St Vincent’s Hospital, Sydney, AustraliaDirector, Australian Tobacco Harm Reduction Association Ambassador, Harm Reduction AustraliaDrug Harm Reduction: What is it? Does it Work? Is it Safe?
27Presentation Abstracts27 October 2024 (Sunday)Abstract:This lecture explores the complexities of bipolar depression, particularly focusing on mixed episodes. It begins with an introduction to bipolar depression, outlining its key characteristics and impact on individuals. The discussion then delves into mixed episodes, highlighting their features and the significance of recognizing mixed features in clinical practice.Treatment options for mixed episodes are examined, with a special emphasis on the eicacy of lurasidone, a medication that has shown promise in managing depressive symptoms. This lecture also addresses the neurobiological mechanisms of lurasidone, specifically its interaction with glutamate and HT-7 receptors, and the implications these have for treatment outcomes.Furthermore, the impact of weight and metabolic health in individuals with bipolar disorder will be discussed, focusing on how various treatments can influence these factors. The session concludes with two case studies that illustrate the practical application of these concepts in clinical settings, showcasing the eectiveness of lurasidone in managing mixed episodes while maintaining metabolic health.Dr. Pongsatorn PAHOLPAKPsychiatrist, Attending physician, Department of Psychiatry Faculty of Medicine, Khon Kaen University, ThailandUnderstanding Mixed States in Bipolar Disorder
28Presentation Abstracts27 October 2024 (Sunday)Abstract:In this thought-provoking presentation, Prof. M. S. Reddy will explore the tentative paradigm shi in the prophylaxis of Bipolar Disorders, addressing the question, “Are we ready?” He will examine the evolving landscape of bipolar disorder treatment, emphasizing the need for a comprehensive approach that incorporates recent advancements in research. Prof. Reddy will discuss the limitations of traditional treatment models and highlight innovative strategies that have emerged.Prof. Reddy will present evidence-based practices and novel therapeutic options that aim to enhance overall quality of life for patients. Special focus will be on two recent publications in the oicial journal of ISBD “Bipolar Disorders”1. EDITORIALAnnemiek Dols, Ralph W. Kupka, Henk Mathijssen, Eline J. Regeer, “The time has come to question the infinite maintenance treatment for bipolar disorders”Bipolar Disord. 2024;26:415–417.2. EDITORIALSergio A. Strejilevich, Cecilia Samamé, Danilo Quiroz,“The Neuroprogression hypothesis in BD: Time for Apologies?”Bipolar Disord. 2023;25:353354.Attendees will gain insights into the current state of bipolar disorder management and be encouraged to reflect on their own practices in light of the emerging evidence. This session promises to inspire mental health professionals to embrace innovative strategies in the treatment of bipolar disorder, ultimately aiming for better outcomes and improved care for those aected by this complex condition.Prof. M.S. REDDYConsultant Psychiatrist, Asha Hospital, IndiaParadigm Shift in the Management of Bipolar Disorders - Are We Ready?
29Presentation Abstracts27 October 2024 (Sunday)Abstract:This talk explores the role of antidepressants in achieving full functional recovery for patients with Major Depressive Disorder (MDD). While symptom alleviation is critical, eective treatment must also focus on enhancing daily functioning and quality of life. We will examine recent advancements in antidepressant therapies, including SSRIs, SNRIs, and novel agents, e.g. vortioxetine, emphasizing their mechanisms of action and impact on functional outcomes, particularly in working population. Dr. Tak-Lam LOSpecialist in Psychiatry, HKAchieving Full Functional Recovery and Additional Treatment Goals for Patients with Major Depressive Disorder (MDD)
30Presentation Abstracts27 October 2024 (Sunday)Abstracts:In this engaging lunch symposium, Prof. M. S. Reddy will delve into the application of Transcranial Magnetic Stimulation (TMS) as a treatment modality for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD). He will provide an overview of TMS, a non-invasive brain stimulation technique that has gained recognition for its eicacy in managing treatment-resistant cases of MDD and OCD. Prof. Reddy will discuss the underlying mechanisms of TMS, including its ability to modulate neural activity and connectivity in brain regions associated with mood regulation and anxiety.The presentation will highlight recent clinical findings and meta-analyses that support the use of repetitive TMS (rTMS). Prof. Reddy will also address the practical aspects of TMS treatment, including patient selection, treatment protocols, and the integration of TMS into existing therapeutic frameworks. By sharing insights from current research and clinical practice, he aims to equip mental health professionals with a deeper understanding of TMS’s role in enhancing treatment outcomes for individuals, ultimately improving patient care and quality of life.Prof. M.S. REDDYConsultant Psychiatrist, Asha Hospital, IndiaTranscranial Magnetic Stimulation (TMS) in the Treatment of MDD & OCD Leespharm_Adasuve_ads-v1-FA-em-OL.pdf 1 11/10/2024 上午9:51
Leespharm_Adasuve_ads-v1-FA-em-OL.pdf 1 11/10/2024 上午9:51
33General InformationCONFERENCE LANGUAGEAANP Regional Scientific Conference 2024 will be executed in English.CERTIFICATE OF ATTENDANCEAer fully completing the Conference, attendees will receive the e-Certificate of attendance via their registered email accounts within 7 days aer the Conference.DISCLAIMERWhilst every eort will be made to ensure that the Conference will take place as described in the programme, the Organizing Committee reserves the right to change the programme and related arrangements without prior notice as and when deemed necessary.The presentations or information provided by speakers and moderators at the Conference represent their personal opinions and do not necessarily represent those of the Conference or its organizers. The Conference and its organizers shall not be held liable for any errors, omissions, misstatements or misrepresentations, whether expressed or implied, of any information shared at the Conference.PROHIBITIONWe kindly remind all attendees that the presentations and videos shown during the Conference are strictly prohibited from being captured or photographed under any circumstances. Unauthorized reproduction or distribution of the content is strictly prohibited. Thank you for your cooperation in respecting this policy.
34Notes
35Notes
36Notes
37Acknowledgement